← boardnext 2027-02-01
TVRD
Tvardi Therapeutics, Incorporateddistress 4/10 · elevated risk$2.66-4%today-94% from 52w high
Respiratory 1
Lead: Hepatocellular Carcinoma
Revenue
pre-revenue
Liquidity
$25M
Runway
1.1 yrs
Shares 1y
0%
Price & events
-44.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.6%
1D
-13.6%
1W
+9.9%
1M
-11.6%
3M
-43.3%
6M
-90.7%
1Y
-80.5%
2Y
-99.4%
5Y
-99.5%
All
Overview
- Market Cap
- $24.95M
- Volume
- 132.42K
- 52 Week Range
- $1.50 – $42.98
- Total Shares
- 9.38M
- Float Shares
- 5.67M
- Short %
- 5.44%
- % Held by Insiders
- 34.64%
- % Held by Institutions
- 28.93%
- RVOL
- 0.03x
Pipeline stages · 1 programs
TTI-101, Pembrolizumab, Atezolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-02-01 Estimated 50% readout ~2027-03-18 | Phase 1/2 | TTI-101, Pembrolizumab, Atezolizumab | Hepatocellular Carcinoma | — | recruiting |
| 2025-08-14 | Phase 2 | TTI-101, Placebo | Idiopathic Pulmonary Fibrosis | 100 | completed |
Catalyst news & presentations · 7
- 2026-08-13earningsEarningsEarnings releaseyahoo
- 1H:2026readoutPhase 1/2TTI-101 · Topline data from Phase 1b/2 trial in hepatocellular carcinoma.SEC 8-K
- 1H:2026readoutPhase 1/2Tvardi HCC candidate · Phase 1b/2 topline dataSEC 8-K
- 2H:2025readoutPhase 2Tvardi IPF candidate · Unblinded Phase 2 dataSEC 8-K
- 4Q 2025readoutPhase 2TTI-101 · Topline data from REVERT IPF trialSEC 8-K
- 2025-04-11partnershipMerger between Tvardi and Cara Therapeutics announced; S-4 effective Feb 14, 2025; merger expected to close mid-April 2025SEC 8-K
- 2024-12-17partnershipCara Therapeutics and Tvardi Therapeutics entered into an Agreement and Plan of Merger and Reorganization.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $10 (+267% upside) · 8 analysts
- 2026-07-08Raymond JamesMarket Perform → Outperform
- 2026-07-07BTIGBuy
- 2026-06-08HC Wainwright & Co.Buy
- 2026-04-20BarclaysEqual-Weight → Underweight
- 2026-04-01Piper SandlerNeutral
- 2026-04-01BTIGBuy
Competitors — Hepatocellular Carcinoma
- ABBVAbbVie Inc.$451.1B · D2
- PFEPFIZER INC$142.2B · D3
- EXELEXELIXIS, INC.$13.8B · D0
- TYRATyra Biosciences, Inc.$1.8B · D3
- ZYMEZymeworks Inc.$1.7B · D1
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- CHRSCoherus Oncology, Inc.$218M · D7
- TPSTTempest Therapeutics, Inc.$14M · D10
- SNTISenti Biosciences Holdings, Inc.$14M · D5
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-17Tvardi Therapeutics Expands At-The-Market Equity Program - TipRanks
- 2026-07-17Tvardi Therapeutics (TVRD) plans up to $9.7M Nasdaq at-the-market stock offering - Stock Titan
- 2026-07-13Tvardi Therapeutics, Inc. (NASDAQ: TVRD) Share Price, TVRD Stock News, TVRD Share Price & Updates - Kalkine
- 2026-07-13Enterprise value to revenue forward of Tvardi Therapeutics Inc. – BX:TVRD - TradingView
- 2026-07-11Tvardi Therapeutics (TVRD) Proxy filing Summary - Quartr
- 2026-07-11Tvardi Therapeutics (TVRD) Proxy filing Summary - Quartr
- 2026-07-10Tvardi Therapeutics (TVRD) Slides 3.68% as Stock Tests Key Support Levels - Catalyst Driven Stocks - dars.gov.et
- 2026-07-09Why Is Tvardi Therapeutics Stock Falling Thursday? - Sahm
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.